Neurotensin and its amide analogue [Gln4]-neurotensin: effects on brain monoamine turnover. 1978

J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers

Intracerebroventricularly administered neurotensin and [Gln4]-neurotensin (50-200 microgram) increased the formation of Dopa in different brain regions of rats after inhibition of the aromatic L-amino acid decarboxylase. For both neuropeptides these increases were dose dependent (20-150%). In the corpus striatum [Gln4]-neurotensin was twice as active as neurotensin and it tended to be more active also in other brain regions. The brain tyrosine concentrations were also increased. [Gln4]-neurotensin (100-200 microgram) following inhibition of the aromatic L-amino acid decarboxylase, increased the accumulation of 5-hydroxytryptophan in all brain regions by 30-60%. In contrast, neurotensin was completely inactive. In both cases the brain tryptophan concentrations were increased. Both neurotensin and [Gln4]-neurotensin also accelerated the disappearance of dopamine, noradrenaline and 5-hydroxytryptamine after inhibition of monoamine synthesis. These results show an increased brain monoamine turnover induced by both neuropeptides.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D009496 Neurotensin A biologically active tridecapeptide isolated from the hypothalamus. It has been shown to induce hypotension in the rat, to stimulate contraction of guinea pig ileum and rat uterus, and to cause relaxation of rat duodenum. There is also evidence that it acts as both a peripheral and a central nervous system neurotransmitter.
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D001679 Biogenic Amines A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology. Amines, Biogenic,Biogenic Amine,Amine, Biogenic
D014364 Tryptophan An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals. Ardeydorm,Ardeytropin,L-Tryptophan,L-Tryptophan-ratiopharm,Levotryptophan,Lyphan,Naturruhe,Optimax,PMS-Tryptophan,Trofan,Tryptacin,Tryptan,Tryptophan Metabolism Alterations,ratio-Tryptophan,L Tryptophan,L Tryptophan ratiopharm,PMS Tryptophan,ratio Tryptophan
D014443 Tyrosine A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin. L-Tyrosine,Tyrosine, L-isomer,para-Tyrosine,L Tyrosine,Tyrosine, L isomer,para Tyrosine

Related Publications

J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
November 1976, Proceedings of the National Academy of Sciences of the United States of America,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
August 1977, Acta pharmacologica et toxicologica,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
December 1976, Acta physiologica Scandinavica,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
November 1976, Psychopharmacology,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
November 1980, Acta physiologica Scandinavica,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
October 1987, The American journal of physiology,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
January 1990, Psychopharmacology bulletin,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
August 1983, Acta physiologica Scandinavica,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
February 1996, Psychopharmacology,
J A García-Sevilla, and T Magnusson, and A Carlsson, and J Leban, and K Folkers
June 1971, European journal of pharmacology,
Copied contents to your clipboard!